3,084 press releases indexed under healthcare.
Real-world data from 141 Medicare patients shows significant gains in cognitive function and quality of life through a highly accessible delivery model designed to reach rural neurology deserts LONDON, July 12, 2026 /PRNewswire/ -- Moneta Health, a brain health company delivering...
(PR-inside.com) MALMÖ, SE / ACCESS Newswire / July 12, 2026 / Ascelia Pharma (STO:ACE) - Ascelia Pharma AB (publ) (STO:ACE), a biopharmaceutical company focused on improving the lives of people living with rare cancer conditions, provides an update following the recent publication of the Complete Response Letter (CRL) by the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Orviglance®. As previously communicated, Ascelia Pharma ("Ascelia") is preparing for a Type A meeting with the FDA to obtain a detailed understanding of the matters outlined in the CRL and to find an expedited path forward for Orviglance. Ascelia views ..
Five-day medical mission highlights the critical role of physical therapy in restoring patient mobility and improving access to care PORTLAND, Maine, July 12, 2026 /PRNewswire-PRWeb/ -- Earlier this year, physical therapist Andrew Genova, PT, DPT, Managing Partner at MVPT Physical...
HDT Bio Canada Inc. partners with McGill University and The Neuro to advance HDT-401, an investigational locally administered RNA immune activator, into Phase 1 clinical evaluation for glioblastoma in Canada MONTREAL and SEATTLE, July 12, 2026 /PRNewswire/ -- Among the deadliest of brain...
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE, Mass., July 12, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB)...
Next-generation cloud platform cuts administrative burdens for mobile clinical workforces while embedding seamless, secure data collection tools at the patient bedside. [PR.com]
Dr. Nathan Merriman, Intermountain Health, explains the risk of Gastroesophageal Reflux Disease and how it increases the risk of Esophageal Cancer The post Frequent Heartburn or Reflux Can Be a Sign of Something More Serious, Says Intermountain Health first appeared on
(PR-inside.com) " DEA silenced the only FDA-pathway cannabinoid developer at its ALJ hearing. The courts won't." - Duane Boise, CEO, MMJ International Holdings. WASHINGTON, D.C. / ACCESS Newswire / July 12, 2026 / The most revealing moment of the DEA's marijuana rescheduling process may not have occurred during seven days of testimony in Arlington. It occurred weeks earlier, when the DEA decided who would not be allowed into the hearing room. The agency excluded MMJ International Holdings-the only company developing botanical cannabinoid medicines through the FDA's formal drug approval process-from participating in a hearing whose central question was whether marijuana has a "currently ..
" DEA silenced the only FDA-pathway cannabinoid developer at its ALJ hearing. The courts won't." - Duane Boise, CEO, MMJ International Holdings .
COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.
Research Highlights : A lab study investigating mouse and human cardiac tissue found a potential link between gum disease (periodontitis) and a narrowing of the aortic valves (aortic valve stenosis). Currently, there is no medication or treatment available that can prevent or slow the progression of aortic valve stenosis. However, these findings suggest that treating gum disease and associated inflammation of the gums might help prevent the most common form of heart valve disease. Note: The study featured in this news release is a research abstract. Abstracts presented at the American Heart Association’s scientific meetings are not peer-reviewed, and the findings are considered preliminary until published as full manuscripts in a peer-reviewed scientific journal. Embargoed until 8 a.m. CT/